These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Liu J; Zhao XS; Liu YR; Xu LP; Zhang XH; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Liu KY; Fan QZ; Huang XJ; Chang YJ Chin Med J (Engl); 2018 Dec; 131(23):2808-2816. PubMed ID: 30511683 [TBL] [Abstract][Full Text] [Related]
6. Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia. Orvain C; Wilson JA; Fang M; Sandmaier BM; Rodríguez-Arbolí E; Wood BL; Othus M; Appelbaum FR; Walter RB Haematologica; 2023 Feb; 108(2):420-432. PubMed ID: 35924583 [TBL] [Abstract][Full Text] [Related]
7. Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors. Narlı Özdemir Z; Şahin U; Dalva K; Baltacı MA; Uslu A; Öztürk C; Cengiz Seval G; Toprak SK; Kurt Yüksel M; Topçuoğlu P; Arslan Ö; Özcan M; Beksaç M; İlhan O; Gürman G; Civriz Bozdağ S Turk J Haematol; 2021 Jun; 38(2):111-118. PubMed ID: 33112099 [TBL] [Abstract][Full Text] [Related]
8. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321 [TBL] [Abstract][Full Text] [Related]
10. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. Walter RB; Gooley TA; Wood BL; Milano F; Fang M; Sorror ML; Estey EH; Salter AI; Lansverk E; Chien JW; Gopal AK; Appelbaum FR; Pagel JM J Clin Oncol; 2011 Mar; 29(9):1190-7. PubMed ID: 21282535 [TBL] [Abstract][Full Text] [Related]
11. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation. Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830 [TBL] [Abstract][Full Text] [Related]
12. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272 [TBL] [Abstract][Full Text] [Related]
13. DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant. Dillon LW; Gui G; Page KM; Ravindra N; Wong ZC; Andrew G; Mukherjee D; Zeger SL; El Chaer F; Spellman S; Howard A; Chen K; Auletta J; Devine SM; Jimenez Jimenez AM; De Lima MJG; Litzow MR; Kebriaei P; Saber W; Weisdorf DJ; Hourigan CS JAMA; 2023 Mar; 329(9):745-755. PubMed ID: 36881031 [TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation. Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162 [TBL] [Abstract][Full Text] [Related]
15. Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia. Aitken MJL; Ravandi F; Patel KP; Short NJ J Hematol Oncol; 2021 Sep; 14(1):137. PubMed ID: 34479626 [TBL] [Abstract][Full Text] [Related]
16. Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation. Getta BM; Devlin SM; Levine RL; Arcila ME; Mohanty AS; Zehir A; Tallman MS; Giralt SA; Roshal M Biol Blood Marrow Transplant; 2017 Jul; 23(7):1064-1071. PubMed ID: 28315400 [TBL] [Abstract][Full Text] [Related]
17. Prognostic value of combined WT1 and multiparameter flow cytometry assessment for measurable residual disease after induction in non-APL acute myeloid leukemia. Ding Y; Liu Z; Wang H; Xiong S; Zhai Z Scand J Clin Lab Invest; 2023 Sep; 83(5):340-347. PubMed ID: 37355341 [TBL] [Abstract][Full Text] [Related]
19. [Clinical Study on Dynamic Detection of Minimal Residual Disease in Acute Myeloid Leukemia by Multiparameter Flow Cytometry]. Jin Y; Wang AY; Wang XB; Yang HZ; Liu X Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):737-743. PubMed ID: 35680798 [TBL] [Abstract][Full Text] [Related]
20. Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation. Lucero J; Alhumaid M; Novitzky-Basso I; Capo-Chichi JM; Stockley T; Gupta V; Bankar A; Chan S; Schuh AC; Minden M; Mattsson J; Kumar R; Sibai H; Tierens A; Kim DDH Ann Hematol; 2024 Apr; 103(4):1187-1196. PubMed ID: 38291275 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]